Ona Therapeutics

Ona Therapeutics is a biotechnology company that develops first-in-class antibody drug conjugates (ADCs) and monoclonal antibodies to treat advanced, treatment-refractory cancers. The company identifies novel therapeutic targets by analyzing the molecular changes in cancer cells from patients who have become resistant to standard care. Its pipeline includes programs targeting breast cancer and other solid tumors, including a specific monoclonal antibody against the metabolic regulator CD36.